Browse the evidence

Short-term periods of physical inactivity (disuse) accelerate muscle atrophy and strength loss in older adults, mimicking years of natural aging.

Avoid prolonged periods of inactivity, such as bedrest or hospitalization, as they cause rapid muscle loss in older adults that is difficult to reverse. Maintain daily movement even during minor illnesses or injuries.

Drop set training produces similar muscular strength and hypertrophy adaptations compared to traditional training, while offering greater time efficiency.

If you are short on time, drop sets are a valid alternative to traditional sets for building muscle and strength. You do not need to sacrifice results for speed. Perform exercises to failure, then immediately reduce the weight by 10-20% and continue to failure. This can reduce your workout time by 30-70% while producing similar adaptations to traditional training. Note that current evidence is limited to young men.

GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide) induce significant weight loss (≥10%) and reduce major adverse cardiovascular events (MACE) in patients with obesity, outperforming conventional anti-obesity drugs and lifestyle modification alone.

If you have obesity and are at risk for heart disease, GLP-1 receptor agonists like semaglutide or liraglutide are currently the most effective pharmacological options for achieving significant weight loss (often >10%) and reducing cardiovascular risk. Unlike older weight-loss drugs or lifestyle changes alone, these medications address the hormonal drivers of weight regain and offer specific heart benefits. However, they require long-term use to maintain results, and treatment should be discussed with a healthcare provider to weigh benefits against costs and side effects.

Tirzepatide, a GIP/GLP-1 receptor agonist, achieves unprecedented reductions in HbA1c and clinically significant weight loss in Type 2 Diabetes patients, with a substantial proportion achieving normoglycemia without hypoglycemia.

Tirzepatide is a once-weekly injection that significantly lowers blood sugar and promotes substantial weight loss in people with Type 2 Diabetes, often without causing low blood sugar. It is designed to be started at a low dose and gradually increased to minimize side effects like nausea. This treatment challenges the old view that effective diabetes management requires insulin or causes weight gain.

Multi-receptor incretin drugs (Tirzepatide, Retatrutide, Mazdutide, Survodutide) produce substantial weight loss (>8kg) and glycemic control (HbA1c reduction >1%) in adults with overweight/obesity, with non-diabetic populations showing more pronounced effects than those with type 2 diabetes.

If you have overweight or obesity, multi-receptor incretin drugs like Tirzepatide or Retatrutide are highly effective for significant weight loss (often >10kg) and improving blood sugar control. These benefits are even more pronounced if you do not have type 2 diabetes. While gastrointestinal side effects are common, serious safety risks are not significantly higher than placebo. Consult a healthcare provider to determine if these medications are appropriate for your specific health profile.

Diabetes-specific nutrition formulas (DSNFs) containing slowly-digestible carbohydrates and healthy fats significantly reduce postprandial glucose and insulin excursions compared to standard formulas or isocaloric test meals in patients with type 2 diabetes.

For Type 2 Diabetes, replacing one or two meals/snacks daily with a Diabetes-Specific Nutrition Formula (DSNF) can significantly improve blood sugar control compared to standard formulas or regular food. Look for formulas with slowly-digestible carbs and healthy fats. Dosing should be tailored to your weight and current blood sugar levels, typically 1-3 servings per day.

Adopting a proinflammatory diet (Energy-Adjusted Dietary Inflammatory Index > 0) is associated with significantly increased risks of all-cause mortality, cardiovascular disease, and cancer, whereas maintaining a neutral or anti-inflammatory diet minimizes these risks.

Focus on avoiding proinflammatory foods rather than striving for a perfect anti-inflammatory diet. A neutral diet is likely sufficient to minimize your risk of heart disease and early death. Small, sustainable improvements to reduce inflammatory potential are more effective and maintainable than extreme dietary restrictions.

A Mediterranean-style diet with high unsaturated fats and low carbohydrates reduces epicardial fat volume, whereas a standard low-calorie diet and exercise alone do not.

Adopting a Mediterranean-style diet (high in unsaturated fats, low in carbs) can reduce epicardial fat in obese HFpEF patients, even without significant weight loss. Combine this with physical activity for best results. Avoid standard low-calorie diets if they do not reduce EAT.

Sustained weight loss of 15 kg or more through structured lifestyle interventions (such as total meal replacement diets) can induce remission of type 2 diabetes in early-stage patients.

If you have early-stage type 2 diabetes, losing a significant amount of weight (around 15 kg or 33 lbs) through a structured program can potentially put your diabetes into remission. This often involves a short period of very low-calorie intake (around 800-850 calories/day) using meal replacements, followed by a careful return to normal food. This is most effective when done under professional guidance and is most likely to work if you haven't had diabetes for very long.

Pharmacological interventions with GLP-1 receptor agonists (e.g., semaglutide 2.4 mg, tirzepatide) and SGLT2 inhibitors promote weight loss and improve glycemic control, contributing to diabetes remission and reduced cardiovascular/renal risks.

If lifestyle changes alone aren't enough to control your diabetes or help you lose weight, ask your doctor about GLP-1 medications like semaglutide or tirzepatide. These are weekly injections that help you lose weight and can put type 2 diabetes into remission for many people. They also protect your heart and kidneys. They are not just 'diet pills' but powerful tools for managing the disease.

Obesity is a root cause of type 2 diabetes, and weight loss reduces the risk of microvascular complications (retinopathy, nephropathy) and improves renal function.

Keeping your weight down is one of the most important things you can do to protect your eyes and kidneys from diabetes-related damage. Even modest weight loss can significantly lower your risk of these serious complications. This is because excess fat contributes to inflammation and stress on these organs.

Semaglutide 2.4 mg combined with diet and exercise is cost-effective for adults with obesity (BMI ≥ 30 kg/m²) and comorbidities in Portugal, yielding 0.098 QALYs gained at an ICER of 13,459 EUR per QALY compared to diet and exercise alone.

For patients with obesity and comorbidities in Portugal, adding semaglutide 2.4 mg to diet and exercise is a cost-effective strategy that improves quality-adjusted life years compared to diet and exercise alone, particularly for those with BMI ≥ 30 kg/m².

Achieving early weight loss of ≥10% body weight in newly diagnosed type 2 diabetes significantly increases the likelihood of diabetes remission and sustains glycaemic improvements compared to losing <10%.

For newly diagnosed type 2 diabetes, aiming for a 10% body weight loss within the first five years is a critical threshold. This specific magnitude of loss is strongly associated with a 4-fold increase in the chance of achieving diabetes remission and sustained lower HbA1c levels compared to smaller weight losses.

Theory-based lifestyle interventions combining dietary and physical activity components with specific behavior change techniques (goal setting, self-monitoring, instructions, credible source) are effective for treating overweight/obesity in post-treatment breast cancer survivors.

Breast cancer survivors aiming for weight loss should engage in structured lifestyle programs that combine a moderate caloric deficit (500-1000 kcal/day) with gradually increasing physical activity (starting at 30 mins/day). These programs must be grounded in behavioral theory and explicitly use techniques like goal setting, self-monitoring, and credible instruction to be effective.

GLP-1 Receptor Agonists (specifically Semaglutide) induce significant weight loss (10-15%) and improve metabolic and endocrine markers (including menstrual regularity and insulin sensitivity) in women with PCOS, although long-term sustainability requires continued treatment.

Semaglutide (a GLP-1 RA) is an effective treatment for women with PCOS who are obese and haven't succeeded with lifestyle changes alone. It promotes significant weight loss (approx. 11-15 kg) and can restore menstrual regularity and improve insulin sensitivity. However, stopping the medication often leads to partial weight regain, suggesting it may need to be a long-term therapy for sustained benefits.

Tirzepatide, a GLP-1/GIP receptor co-agonist, produces superior weight loss and glycemic control compared to selective GLP-1 receptor agonists and insulin in patients with type 2 diabetes.

If you have type 2 diabetes, tirzepatide is a once-weekly injection that lowers blood sugar and helps you lose more weight than older diabetes medications. It is generally well-tolerated, though you may experience gastrointestinal side effects. Discuss with your doctor if this once-weekly option is right for you.

When higher training frequency allows for greater total training volume (unequalized volume), higher frequency yields greater strength and hypertrophy gains due to the volume increase.

If you choose to train a muscle group 3 times a week, you likely will get better results than training it once, but this is because you can perform more total sets (volume). If you can match the total volume of the 3x/week program in a single 1x/week session, the frequency itself adds no extra benefit.

A single dose of a creatine-based multi-ingredient pre-workout supplement (MIPS) containing 3g creatine, 2g arginine, 1g glutamine, 1g taurine, and 800mg beta-alanine improves performance fatigability (measured by time to task and EMG conduction velocity) compared to placebo when ingested 2 hours before resistance exercise.

If you take a pre-workout containing creatine, beta-alanine, arginine, glutamine, and taurine, taking it 2 hours before your workout may help you sustain effort longer during high-intensity resistance training compared to taking a placebo. However, taking just creatine alone (3g) 2 hours before the workout did not show the same benefit, and the multi-ingredient mix was not superior to creatine alone in this study. Focus on the timing (2 hours prior) and the specific mix if you seek acute fatigue resistance.

Supervised resistance training produces greater site-specific muscle hypertrophy and strength gains compared to unsupervised training in resistance-trained individuals.

If you are already experienced with resistance training, working with a coach or trainer who provides real-time feedback and encouragement will likely lead to better muscle growth and strength gains than training alone. The supervision helps you push closer to failure with better technique, which drives adaptation.

Higher training volumes impose greater recovery demands, particularly when combined with proximity to failure, requiring strategic placement within the microcycle to avoid performance impairment in subsequent sessions.

Start with moderate volume (e.g., 10-15 sets per muscle group per week) and monitor recovery. If performance drops or fatigue accumulates, reduce volume before increasing it. Prioritize volume on less critical days or for specific muscle groups (specialization) while keeping other volumes lower.

Daily undulating programming (DUP) and strategic microcycle construction (e.g., prioritizing high-intensity sessions after low-intensity recovery sessions) can optimize recovery and enhance performance on priority sessions.

Use Daily Undulating Programming (DUP) to schedule high-intensity or high-volume sessions after low-intensity 'easy' sessions. This allows you to recover fully for your priority lifts while maintaining training frequency.

High-intensity exercise training (77-95% max HR) improves walking performance and cardiorespiratory fitness more than low-intensity training in PAD patients.

To maximize your walking distance, aim for high-intensity exercise. Target 77-95% of your maximum heart rate or a Borg scale rating of 14-17. This may involve significant leg pain, which is expected and part of the adaptation process.

Tirzepatide achieves body weight loss of ≥ 5% significantly faster than semaglutide 1 mg in patients with type 2 diabetes.

If your goal is weight loss alongside blood sugar control, tirzepatide (10 or 15 mg) will likely get you to a 5% body weight reduction in about 12 weeks, which is half the time it takes with semaglutide 1 mg. This benefit persists despite the slower dose escalation schedule required to manage side effects.

Semaglutide 2.4 mg administered subcutaneously once-weekly produces significant body weight reduction (mean 12.2 kg or 11.8%) and improves cardiometabolic parameters in adults with obesity, with real-world evidence confirming efficacy similar to randomized controlled trials.

Semaglutide 2.4mg once weekly is a highly effective treatment for obesity, producing an average 12kg weight loss when combined with lifestyle changes. Real-world data confirms it works as well as in clinical trials. Be aware of common side effects like nausea, which often subside, and discuss cost-effectiveness with your provider as it varies by region and insurance.